FDA clears digital therapeutic for abdominal pain from IBS
MetaMe received FDA clearance for its first digital therapeutic on Tuesday. It uses behavioral therapy to help alleviate abdominal pain symptoms for patients with irritable bowel syndrome.
MetaMe received FDA clearance for its first digital therapeutic on Tuesday. It uses behavioral therapy to help alleviate abdominal pain symptoms for patients with irritable bowel syndrome.
Oshi Health raised $23 million in funding, with CVS Health and Takeda joining as strategic investors. The company has built a digital health platform to help people manage GI conditions, such as Crohn’s disease and IBS.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company's lead product Regulora delivers a standardized 12-week therapy which bring patients into a state of deep relaxation and suggestibility before using metaphors and stories to create a sense of comfort and ease around the individual's condition and symptoms.